In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
World Animal Protection launches AI-Powered cultivated meat chatbot
In London, animal advocacy group World Animal Protection has partnered with AI software company PubTrawlr to unveil Cultivator, the first-ever chatbot dedicated to cultivated...
DOE awards Hempitecture $8.42 million to boost hemp fiber manufacturing in Tennessee
In Idaho, sustainable building materials firm Hempitecture has been awarded $8.42 million in funding from the U.S. Department of Energy under the Biden-Harris Administration’s...
CJ Biomaterials PHA earns compostability certification
In Massachusetts, CJ Biomaterials, a division of South Korea's CJ CheilJedang, has received certification from the Biodegradable Products Institute (BPI) for its range of...